-6.4%
AMT vs MRNA
+511.3%
-517.7%
-15.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.1% | -2.2% | +1.2% | -1.1% |
| 7D | -0.2% | +5.5% | -5.7% | -0.3% |
| 30D | +4.6% | +158.7% | -154.1% | +3.0% |
| 3M | -8.4% | +182.1% | -190.6% | -10.5% |
| 6M | -6.0% | +151.8% | -157.8% | -7.6% |
| YTD | +2.1% | +393.6% | -391.4% | -4.3% |
| 1Y | -6.4% | +499.5% | -505.8% | -14.4% |
| All | -6.4% | +511.3% | -517.7% | -14.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling